EAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary clinical data from its phase 2 study in chemo-refractory metastatic triple negative breast cancer at the American Society of Clinical Oncology (ASCO) 2019 annual meeting, May 31-June 4 in Chicago.
The study is evaluating Imprime PGG in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy from Merck & Co., Inc. (known as MSD outside the United States and Canada), in triple negative breast cancer patients whose disease has progressed following treatment with one or more lines of chemotherapy for metastatic disease. The study is being conducted under a clinical collaboration agreement between Biothera and Merck.
Poster presentation details are as follows:
Poster Title: An open label, multicenter phase II study combining Imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (MSNBC).
Abstract Number: #2550
Session: Developmental Immunotherapy and Tumor Immunobiology
Date and Time: Saturday, June 1, 8:00 AM-11:00 AM CDT
Location: Hall A
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation and infiltration into tumors, and to enhance clinical benefit from immune checkpoint inhibitors. Biothera Pharmaceuticals is currently developing this platform drug through clinical research collaborations with Merck, Genentech, the Dana Farber Cancer Institute and the Big Ten Cancer Research Consortium in cancers that include triple negative breast cancer, advanced melanoma, colorectal cancer and non-small lung cell cancer.
Contact:
Jeremy Graff, Ph.D.
President and Chief Scientific Officer
Biothera Pharmaceuticals, Inc.
651-675-0300
jgraff@biothera.com